Assignee
XOMA TECHNOLOGY LTD
US·49 granted patents·20 pending applications·573 citations·filing 1995–2023
Top patents by PatentIndex Score
69 records- 0197US7531166B2IL-1β binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2006·Granted May 12, 2009·49 cites·10 claims
- 0296US7744865B2IL1-β Binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Jun 29, 2010·23 cites·10 claims
- 0396US7582742B2Method of treating or preventing an IL-1 related disease or conditionXOMA TECHNOLOGY LTD·Filed 2008·Granted Sep 1, 2009·23 cites·12 claims
- 0495US7829093B2Method of treating an IL-1 related autoimmune disease or conditionXOMA TECHNOLOGY LTD·Filed 2009·Granted Nov 9, 2010·21 cites·6 claims
- 0595US7695717B2Method of treating an IL-1 related inflammatory disease or conditionXOMA TECHNOLOGY LTD·Filed 2008·Granted Apr 13, 2010·21 cites·22 claims
- 0693US7829094B2Method of treating an IL-1 related cancerXOMA TECHNOLOGY LTD·Filed 2009·Granted Nov 9, 2010·13 cites·12 claims
- 0793US7744866B2IL-1β binding antibodies and binding fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Jun 29, 2010·12 cites·10 claims
- 0893US7695718B2Methods for the treatment of IL-1β related diseasesXOMA TECHNOLOGY LTD·Filed 2007·Granted Apr 13, 2010·19 cites·54 claims
- 0992US8584349B2Flexible manufacturing systemXOMA TECHNOLOGY LTD·Filed 2012·Granted Nov 19, 2013·41 cites·28 claims
- 1092US7943121B2IL-1β binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted May 17, 2011·11 cites·10 claims
- 1192US7094579B2Eukaryotic signal sequences for prokaryotic expressionXOMA TECHNOLOGY LTD·Filed 2002·Granted Aug 22, 2006·24 cites·12 claims
- 1291US6376217B1Fusion proteins and polynucleotides encoding gelonin sequencesXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·18 cites·15 claims
- 1390US7988968B2Method of treating an IL-1 related coronary conditionXOMA TECHNOLOGY LTD·Filed 2009·Granted Aug 2, 2011·7 cites·12 claims
- 1489US9944698B2ModulatorsXOMA TECHNOLOGY LTD·Filed 2014·Granted Apr 17, 2018·5 cites·17 claims
- 1589US7192737B2Methods and materials for increasing expression of recombinant polypeptidesXOMA TECHNOLOGY LTD·Filed 2003·Granted Mar 20, 2007·13 cites·71 claims
- 1689US6376211B1Agents and methods for inhibiting F1/F0 ATPaseXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·38 cites·22 claims
- 1788US9206252B2Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2013·Granted Dec 8, 2015·5 cites·13 claims
- 1888US8377442B2Method of treating inflammatory eye disease with IL-1β binding antibodiesXOMA TECHNOLOGY LTD·Filed 2011·Granted Feb 19, 2013·6 cites·10 claims
- 1988US7977068B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2008·Granted Jul 12, 2011·6 cites·12 claims
- 2088US6495516B1Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 2001·Granted Dec 17, 2002·20 cites·10 claims
- 2187US9145458B2Antibodies specific for TGF-β and methods of treatment thereofXOMA TECHNOLOGY LTD·Filed 2013·Granted Sep 29, 2015·7 cites·24 claims
- 2287US7972811B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2008·Granted Jul 5, 2011·5 cites·12 claims
- 2387US7396661B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2003·Granted Jul 8, 2008·10 cites·12 claims
- 2486US9714285B2TGF-beta-specific antibodies and methods of use thereof for treatmentXOMA TECHNOLOGY LTD·Filed 2015·Granted Jul 25, 2017·4 cites·20 claims
- 2585US7749731B2Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2007·Granted Jul 6, 2010·5 cites·21 claims
- 2685US6803210B2Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoterXOMA TECHNOLOGY LTD·Filed 2001·Granted Oct 12, 2004·11 cites·28 claims
- 2785US6649742B1Immunotoxins comprising ribosome-inactivating proteinsXOMA TECHNOLOGY LTD·Filed 2000·Granted Nov 18, 2003·37 cites·20 claims
- 2885US6500648B1Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2001·Granted Dec 31, 2002·10 cites·19 claims
- 2984US8377429B2Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Feb 19, 2013·5 cites·27 claims
- 3082US10358486B2Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-βXOMA TECHNOLOGY LTD·Filed 2017·Granted Jul 23, 2019·2 cites·20 claims
- 3182US10167334B2Treatment of cancer using anti-TGF-BETA and PD-1 antibodiesXOMA TECHNOLOGY LTD·Filed 2016·Granted Jan 1, 2019·4 cites·15 claims
- 3281US7247454B2Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2002·Granted Jul 24, 2007·6 cites·21 claims
- 3381US6436660B1Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyesXOMA TECHNOLOGY LTD·Filed 2000·Granted Aug 20, 2002·7 cites·8 claims
- 3480US7993915B2Methods and materials for increasing expression of recombinant polypeptidesXOMA TECHNOLOGY LTD·Filed 2007·Granted Aug 9, 2011·2 cites·50 claims
- 3579US6906037B2Therapeutic peptide-based constructsXOMA TECHNOLOGY LTD·Filed 2003·Granted Jun 14, 2005·5 cites·16 claims
- 3678US12071475B2Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatmentXOMA TECHNOLOGY LTD·Filed 2021·Granted Aug 27, 2024·0 cites·19 claims
- 3778US2023416354A1Treatment of cancer using inhibitors of tgf-beta and pd-1XOMA TECHNOLOGY LTD·Filed 2023·Application pending·0 cites
- 3876US6376465B1Therapeutic uses of BPI protein products in BPI-deficient humansXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·5 cites·9 claims
- 3974US10683347B2Treatment of cancer using anti-TGF-β and anti-PD-1 antibodiesXOMA TECHNOLOGY LTD·Filed 2018·Granted Jun 16, 2020·1 cites·16 claims
- 4074US7794976B2Methods and materials for expression of a recombinant proteinXOMA TECHNOLOGY LTD·Filed 2007·Granted Sep 14, 2010·3 cites·36 claims
- 4171US11098111B2Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3XOMA TECHNOLOGY LTD·Filed 2019·Granted Aug 24, 2021·0 cites·24 claims
- 4271US6964948B2Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 2002·Granted Nov 15, 2005·2 cites·61 claims
- 4368US11685775B2Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibodyXOMA TECHNOLOGY LTD·Filed 2020·Granted Jun 27, 2023·0 cites·16 claims
- 4465US2008145895A1Methods and Materials for Increasing Expression of Recombinant PolypeptidesXOMA TECHNOLOGY LTD·Filed 2007·Application pending·0 cites
- 4564US6455271B1Identification of novel antimicrobial agents using membrane potential indicator dyesXOMA TECHNOLOGY LTD·Filed 2000·Granted Sep 24, 2002·19 cites·11 claims
- 4660US6515104B1Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 1999·Granted Feb 4, 2003·11 cites·7 claims
- 4760US6461824B1Production of chimeric antibodies with specificity to human tumor antigensXOMA TECHNOLOGY LTD·Filed 1995·Granted Oct 8, 2002·22 cites·198 claims
- 4859US2003166196A1Fusion proteins and polynucleotides encoding gelonin sequencesXOMA TECHNOLOGY LTD·Filed 2002·Application pending·0 cites
- 4958US2008241126A1Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAMXOMA TECHNOLOGY LTD·Filed 2007·Application pending·0 cites
- 5057US7291451B2Modulation of pericyte proliferationXOMA TECHNOLOGY LTD·Filed 2004·Granted Nov 6, 2007·1 cites·2 claims
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when XOMA TECHNOLOGY LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →